Transitioning individuals with peanut allergy from US Food and Drug Administration-approved peanut oral immunotherapy to a dietary peanut product.

Creator(s)

S Shahzad Mustafa
Jodi Shroba, Children's Mercy Kansas CityFollow

Document Type

Letter to the Editor

Publication Date

1-2023

Identifier

DOI: 10.1016/j.anai.2022.09.037

Journal Title

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Volume

130

Issue

1

First Page

113

Last Page

114

Recommended Citation

Mustafa SS, Shroba J. Transitioning individuals with peanut allergy from US Food and Drug Administration-approved peanut oral immunotherapy to a dietary peanut product. Ann Allergy Asthma Immunol. 2023;130(1):113-114. doi:10.1016/j.anai.2022.09.037